Drug Discovery and Development Strategies for COVID-19

2020 ◽  
Vol 2 (2) ◽  
pp. 1-5
Author(s):  
Aarajana Shrestha ◽  
Tara Man Kadayat
Keyword(s):  
Drug Discovery ◽  
Drug Development ◽  
Development Strategies ◽  
Special Issue ◽  
Medical Sciences ◽  
Drug Discovery And Development ◽  
Current Drug ◽  
The World ◽  
Global Threat ◽  
Effective Drugs

COVID-19 Special Issue: Coronavirus Disease 2019 (COVID-19) has emerged as a global threat. Scientists and clinicians are endeavoring to find effective drugs and vaccines for this disease. This special issue of the Europasian Journal of Medical Sciences (EJMS) aims to cover the problems, solutions, and challenges of COVID-19 around the world. In this Editorial, EJMS Editors Aarajana Shrestha and Tara Man Kadayat highlight the processes of drug discovery and development and a brief overview of the current drug development strategies against COVID-19.

New development and update on China Bioanalysis Forum

Bioanalysis ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 199-201
Author(s):  
Fan Jin ◽  
Daniel Tang ◽  
Kelly Dong ◽  
Dafang Zhong
Keyword(s):  
Drug Discovery ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Drug Development ◽  
Research And Development ◽  
Continuous Growth ◽  
Contract Research Organization ◽  
Drug Discovery And Development ◽  
Medicine Research ◽  
New Development

This article provides an update on new development of China Bioanalysis Forum (CBF). CBF became a member association of Chinese Pharmaceutical Association (CPA) at the end of 2019. The official ceremony and first scientific symposium were held in Shanghai on 18 September 2020. The president of Chinese Pharmaceutical Association and representatives from industry, Contract Research Organization (CRO), hospitals and academic institutes attended the ceremony. Seven experts in the field gave presentations on various topics including Drug Metabolism and Pharmacokinetics (DMPK) and bioanalytical support in drug discovery and development as well as experience in Traditional Chinese Medicine research. With the continuous growth of research and development in China, it is well acknowledged that bioanalysis provides critical support for new innovative medicines and generic drug development in the region.

Kernel Methods in Chemoinformatics

2011 ◽  
pp. 664-668
Author(s):  
Huma Lodhi
Keyword(s):  
Developing Countries ◽  
Drug Discovery ◽  
Drug Design ◽  
Kernel Methods ◽  
Cost Effective ◽  
Activity Relationship ◽  
World Population ◽  
Structure Activity ◽  
The World ◽  
Effective Drugs

Millions of people are suffering from fatal diseases such as cancer, AIDS, and many other bacterial and viral illnesses. The key issue is now how to design lifesaving and cost-effective drugs so that the diseases can be cured and prevented. It would also enable the provision of medicines in developing countries, where approximately 80% of the world population lives. Drug design is a discipline of extreme importance in chemoinformatics. Structure-activity relationship (SAR) and quantitative SAR (QSAR) are key drug discovery tasks.

scholarly journals The Stages of Drug Discovery and Development Process

2019 ◽  
Vol 7 (6) ◽  
pp. 62-67 ◽  
Author(s):  
Amol B Deore ◽  
Jayprabha R Dhumane ◽  
Rushikesh Wagh ◽  
Rushikesh Sonawane
Keyword(s):  
Clinical Trials ◽  
Drug Discovery ◽  
Drug Development ◽  
Development Process ◽  
Regulatory Requirements ◽  
Drug Discovery And Development ◽  
Biological Targets ◽  
New Drug ◽  
Initial Discovery ◽  
New Research

Drug discovery is a process which aims at identifying a compound therapeutically useful in curing and treating disease. This process involves the identification of candidates, synthesis, characterization, validation, optimization, screening and assays for therapeutic efficacy. Once a compound has shown its significance in these investigations, it will initiate the process of drug development earlier to clinical trials. New drug development process must continue through several stages in order to make a medicine that is safe, effective, and has approved all regulatory requirements. One overall theme of our article is that the process is sufficiently long, complex, and expensive so that many biological targets must be considered for every new medicine ultimately approved for clinical use and new research tools may be needed to investigate each new target.  From initial discovery to a marketable medicine is a long, challenging task. It takes about 12 - 15 years from discovery to the approved medicine and requires an investment of about US $1 billion. On an average, a million molecules screened but only a single is explored in late stage clinical trials and is finally made obtainable for patients. This article provides a brief outline of the processes of new drug discovery and development.   

scholarly journals Spread and Dynamics of COVID-19 in the Kingdom of Saudi Arabia and Four Other Countries in the Early Phase: A Study for the Development of the Advanced Health System

2021 ◽  
Author(s):  
Shahanavaj Khan ◽  
Asimul Islam ◽  
Ahmad Firoz ◽  
Anis Ahmad Chaudhary ◽  
Mohammad Amjad Kamal ◽  
...  
Keyword(s):  
Artificial Intelligence ◽  
Saudi Arabia ◽  
Health Policy ◽  
Drug Discovery ◽  
Early Phase ◽  
Kingdom Of Saudi Arabia ◽  
Drug Discovery And Development ◽  
First Case ◽  
Daily Report ◽  
The World

Abstract BackgroundThe epidemic of 2019 novel coronavirus (SARS-CoV-2) is challenge to the world which was at first confirmed in the Wuhan city of China in December 2019. It was declared a pandemic by the World Health Organization (WHO) in March 2020. In the current work we evaluated effect of health policy of Saudi Arabia for the management of COVID-19 pandemic in early phase and compared to other four countries. MethodBased on the Ministry of Health, Kingdom of Saudi Arabia (KSA) data, the summary of daily report of COVID-19 was prepared from 02 March to 30 April 2020. Further, the daily report of enhancement in cases and recovery of the patients was also summarized. Moreover, the incidence, death and recoveries of COVID-19 cases in KSA were compared with major infected country including China, Italy, Spain and United State of America (USA). The important role of artificial intelligence was shown for the development of drug targets against to infectious diseases Results In KSA, the first case of COVID-19 was reported on 02 March 2020. Since then, it has affected 22,753 persons till the end of the April 2020. Also, the results showed that the infection rate of COVID-19 increased continuously during the current period of study in KSA. Nevertheless, the rate of death due to COVID-19 is much less with comparison to China, Italy, Spain, and USA due to good medical facilities along with quick action by the government of KSA after the emergence of first case. There is a dire need to develop new platforms and approaches to combat new and old diseases including COVID-19 at warp speed when compared to traditional approaches. DeepDrug’s approach to drug discovery and development showed brighter future towards the discovery of novel drugs against infectious diseases including COVID-19.ConclusionCurrently, there is higher probability of COVID-19 spread at any place. Therefore good health policy, precautionary measures and medical facility of whole nations should be excellent to combat against the COVID-19 pandemic until the reliable vaccine or antiviral drug developed for the proper treatment of virus. The artificial intelligence (AI) based available process might be very helpful for the drug discovery and development against of old and newly discovered diseases including COVID-19.

Accelerating safe drug development: an ideal approach to approval

Hematology ◽  
2013 ◽  
Vol 2013 (1) ◽  
pp. 24-29
Author(s):  
Michael R. Grever
Keyword(s):  
Drug Discovery ◽  
Drug Development ◽  
Hematologic Malignancies ◽  
Therapeutic Strategies ◽  
Cancer Drug ◽  
Task Completion ◽  
Close Monitoring ◽  
Design Strategies ◽  
Drug Discovery And Development ◽  
Therapeutic Research

Abstract Although enormous progress in therapeutic research has improved the lives of patients with hematologic malignancies, these earlier achievements resulted from strategic combinations of agents with unique mechanisms of action and nonoverlapping toxicities. Continued investment in the modern era of drug discovery and development will focus on targeted therapies. Targeting of specific molecular pathways is expected to achieve effective tumor cell reduction with less overall toxicity. The translational processes involved in moving novel therapeutic strategies from the laboratory toward the clinic require close monitoring. The efforts in both cancer drug discovery and development will require extensive collaboration among basic scientists, clinical investigators, and regulatory scientists. The transition from older methods of therapeutic research will require laboratory support to define eligible patients based upon their pretreatment profile. The principles of preclinical drug development based upon decades of experience in predicting toxicity and designing therapeutic strategies are still needed to insure that safety is a high priority. The opportunities for developing novel targeted combination therapies in uniquely profiled patients will hopefully enable successful breakthroughs. Several concrete examples of exciting new agents are discussed here. Defining the predicted mechanism of resistance to these new targeted agents will enable investigators to subsequently design strategies to circumvent resistance with effective combinations. Drug discovery and development are complex and expensive, so efficiency and cooperation in task completion must be tracked.

Sign in / Sign up

Export Citation Format

Share Document